Medtronic Secures CE Mark for VitalFlow ECMO Air and Ground Transport Frame, Enabling Safer Critical Patient Transfers Across Europe

May 06, 2026 08:00 CST Updated 08:00

Medtronic

Medical Device Manufacturer

MC3 Cardiopulmonary

Cardiopulmonary Equipment Provider

For critically ill patients, every transfer is a race against death—especially for those relying on ECMO (Extracorporeal Membrane Oxygenation) to sustain life, as even the slightest jolt or equipment instability can be life-threatening.

On May 5 (local time), medical giant Medtronic (NYSE: MDT) announced significant good news: its VitalFlow ECMO air-land dual-use transport stent (AG) has officially received CE certification. This means that this "safe mobility" breakthrough technology for ECMO is about to be fully implemented in Europe, providing a strong line of defense for the inter-hospital and cross-regional transport of critically ill patients.

01.What is ECMO?

ECMO, known as the "artificial heart and lung," serves as a "life bridge" in the field of critical care medicine. It can temporarily replace the function of a failing heart and lungs, buying precious time for doctors to treat the primary disease. Its core working logic is "drain-blood—process—reinfuse": deoxygenated venous blood is drained from the patient’s body, passed through a membrane lung for gas exchange to replenish oxygen and remove carbon dioxide, and then the oxygenated blood is reinfused into the body, effectively extending the life support for critically ill patients.

02.Addressing the Clinical Pain Points of ECMO Transport

But ECMO transport has always been a clinical challenge. During traditional transport, equipment is prone to being affected by bumps, leading to issues such as loosened tubing and system instability, all of which could put the patient at risk. The VitalFlow Transport Stretcher AG, newly launched by Medtronic, is precisely aimed at addressing this pain point.

This transport bracket AG is an exclusive accessory of the VitalFlow ECMO system. Its development process has condensed nearly a decade of technical accumulation and refinement. The following chronological summary provides a clearer view of the birth journey of this "life transport" breakthrough technology:

In 2016, Medtronic embarked on an in-depth layout in the ECMO field by establishing a partnership with MC3 Cardiopulmonary, a company focused on the research and development of core ECMO components. Together, they conducted technical exploration and clinical validation, completing over 500 clinical cases, which laid a solid clinical foundation for subsequent product development.
In March 2024, Medtronic completed the strategic acquisition of MC3 Cardiopulmonary for $350 million, fully integrating its core patents and technical team in the fields of membrane oxygenation and hemodynamic control. This marked a significant turning point in the development of the VitalFlow series, with the core technology of the transport bracket AG entering the integration and optimization phase.
In June 2024, the VitalFlow ECMO system was the first to receive CE certification. Medtronic simultaneously advanced the R&D and debugging of the transport bracket AG, integrating MC3's portable design advantages with its own monitoring and control technology. The focus was on addressing core pain points such as equipment stability and compatibility during transport, enhancing dual-use air and land compatibility functions.
From September 2024 to the end of the year, while gradually promoting the VitalFlow ECMO system, Medtronic continues to conduct clinical validation of the AG transport stent, optimizing the stent's protective performance and portability to ensure its compatibility with various transport scenarios such as ambulances, helicopters, and fixed-wing aircraft, meeting actual clinical needs.
On May 5, 2026, after nearly two years of research and development, debugging, and clinical validation, the VitalFlow ECMO Air-Ground Dual-Use Transport Stretcher (AG) officially received CE certification. This marks that the transport accessory has officially obtained market access qualifications in Europe, completing the full closed loop of "research and development—validation—certification" for the VitalFlow system, and is now set to be put into clinical use.

In simple terms, with it, critically ill patients dependent on ECMO can be transferred more safely and smoothly between different hospitals and regions, no longer missing better treatment opportunities due to "excessively high transfer risks."

03.Perfecting the Full-process Life Support Closed Loop

Some may ask, how capable is the VitalFlow ECMO system itself? In fact, as early as June 2024, the system had already received CE certification and was officially launched in Europe that autumn; in September of the same year, Medtronic also began gradually promoting this technology in the United States. After nearly two years of clinical validation, its safety and effectiveness have been recognized by healthcare professionals worldwide.

The recent CE certification of the AG transport stent further enables the VitalFlow system to form a complete closed-loop of "bedside treatment + safe transport," truly achieving full-process life support "from bed to the endpoint of rescue."

According to the plan, Medtronic will officially launch this brand-new transport accessory at the EuroELSO conference held in Dublin this week, allowing this cutting-edge technology to quickly serve critically ill patients worldwide.

Dr. Pieter Kappetein, Chief Medical Officer of Medtronic's Cardiac Surgery and Aortic division, stated: "Every moment is crucial when patients are in critical condition and clinicians are racing against time. By expanding the transport capabilities of ECMO, we are providing stronger support for the treatment of critically ill patients."

ECMO is a "life bridge" for critically ill patients, and this transport bracket AG is the key to making this bridge "mobile." Its emergence not only addresses the pain points of clinical transport but also broadens the boundaries of treatment for critically ill patients — from now on, distance is no longer an obstacle, and every transport can become a "life extension."

Looking forward to the early popularization of this black technology, and hoping that more critically ill patients can receive more timely and safer treatment through it. Also, extending the highest respect to every researcher and medical staff who deeply cultivate medical technology and safeguard lives ❤️

04.Extended Viewpoint: How Critical is ECMO Transport?

According to clinical data, a large number of critically ill patients worldwide require inter-hospital transport each year to receive further treatment, and the safety of ECMO transport directly determines the survival probability of these patients. In developed countries, extensive experience in inter-hospital ECMO transport has been accumulated, but globally, the stability of equipment during transport remains a core challenge. The Medtronic transport bracket, which has received CE certification, may promote the standardized development of global ECMO transport technology, benefiting more patients.